Treatment of optic neuritis with erythropoietin (TONE): a randomised, double-blind, placebo-controlled trial : study protocol

Introduction Optic neuritis leads to degeneration of retinal ganglion cells whose axons form the optic nerve. The standard treatment is a methylprednisolone pulse therapy. This treatment slightly shortens the time of recovery but does not prevent neurodegeneration and persistent visual impairment. I...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Diem, Ricarda (VerfasserIn) , Beisse, Flemming (VerfasserIn) , Drüschler, Katharina (VerfasserIn) , Wildemann, Brigitte (VerfasserIn) , Platten, Michael (VerfasserIn) , Wick, Wolfgang (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 1 March 2016
In: BMJ open
Year: 2016, Jahrgang: 6, Heft: 3
ISSN:2044-6055
DOI:10.1136/bmjopen-2015-010956
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1136/bmjopen-2015-010956
Verlag, lizenzpflichtig, Volltext: https://bmjopen.bmj.com/content/6/3/e010956
Volltext
Verfasserangaben:Ricarda Diem, Fanni Molnar, Flemming Beisse, Nikolai Gross, Katharina Drüschler, Sven P. Heinrich, Lutz Joachimsen, Sebastian Rauer, Amelie Pielen, Kurt-Wolfram Sühs, Ralf Andreas Linker, Cord Huchzermeyer, Philipp Albrecht, Andrea Hassenstein, Orhan Aktas, Tanja Guthoff, Felix Tonagel, Christoph Kernstock, Kathrin Hartmann, Tania Kümpfel, Katharina Hein, Christian van Oterendorp, Birgit Grotejohann, Gabriele Ihorst, Julia Maurer, Matthias Müller, Martin Volkmann, Brigitte Wildemann, Michael Platten, Wolfgang Wick, Christoph Heesen, Ulrich Schiefer, Sebastian Wolf, Wolf A. Lagrèze

MARC

LEADER 00000caa a2200000 c 4500
001 1697732232
003 DE-627
005 20230427190304.0
007 cr uuu---uuuuu
008 200508s2016 xx |||||o 00| ||eng c
024 7 |a 10.1136/bmjopen-2015-010956  |2 doi 
035 |a (DE-627)1697732232 
035 |a (DE-599)KXP1697732232 
035 |a (OCoLC)1341319275 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Diem, Ricarda  |d 1970-  |e VerfasserIn  |0 (DE-588)120119846  |0 (DE-627)080459099  |0 (DE-576)292050992  |4 aut 
245 1 0 |a Treatment of optic neuritis with erythropoietin (TONE)  |b a randomised, double-blind, placebo-controlled trial : study protocol  |c Ricarda Diem, Fanni Molnar, Flemming Beisse, Nikolai Gross, Katharina Drüschler, Sven P. Heinrich, Lutz Joachimsen, Sebastian Rauer, Amelie Pielen, Kurt-Wolfram Sühs, Ralf Andreas Linker, Cord Huchzermeyer, Philipp Albrecht, Andrea Hassenstein, Orhan Aktas, Tanja Guthoff, Felix Tonagel, Christoph Kernstock, Kathrin Hartmann, Tania Kümpfel, Katharina Hein, Christian van Oterendorp, Birgit Grotejohann, Gabriele Ihorst, Julia Maurer, Matthias Müller, Martin Volkmann, Brigitte Wildemann, Michael Platten, Wolfgang Wick, Christoph Heesen, Ulrich Schiefer, Sebastian Wolf, Wolf A. Lagrèze 
264 1 |c 1 March 2016 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 08.05.2020 
520 |a Introduction Optic neuritis leads to degeneration of retinal ganglion cells whose axons form the optic nerve. The standard treatment is a methylprednisolone pulse therapy. This treatment slightly shortens the time of recovery but does not prevent neurodegeneration and persistent visual impairment. In a phase II trial performed in preparation of this study, we have shown that erythropoietin protects global retinal nerve fibre layer thickness (RNFLT-G) in acute optic neuritis; however, the preparatory trial was not powered to show effects on visual function. - Methods and analysis Treatment of Optic Neuritis with Erythropoietin (TONE) is a national, randomised, double-blind, placebo-controlled, multicentre trial with two parallel arms. The primary objective is to determine the efficacy of erythropoietin compared to placebo given add-on to methylprednisolone as assessed by measurements of RNFLT-G and low-contrast visual acuity in the affected eye 6 months after randomisation. Inclusion criteria are a first episode of optic neuritis with decreased visual acuity to ≤0.5 (decimal system) and an onset of symptoms within 10 days prior to inclusion. The most important exclusion criteria are history of optic neuritis or multiple sclerosis or any ocular disease (affected or non-affected eye), significant hyperopia, myopia or astigmatism, elevated blood pressure, thrombotic events or malignancy. After randomisation, patients either receive 33 000 international units human recombinant erythropoietin intravenously for 3 consecutive days or placebo (0.9% saline) administered intravenously. With an estimated power of 80%, the calculated sample size is 100 patients. The trial started in September 2014 with a planned recruitment period of 30 months. - Ethics and dissemination TONE has been approved by the Central Ethics Commission in Freiburg (194/14) and the German Federal Institute for Drugs and Medical Devices (61-3910-4039831). It complies with the Declaration of Helsinki, local laws and ICH-GCP. - Trial registration number NCT01962571. 
650 4 |a Erythropoietin 
650 4 |a Low Contrast Visual Acuity 
650 4 |a Neuroprotection 
650 4 |a Optic neuritis 
650 4 |a Optical coherence tomography 
700 1 |a Beisse, Flemming  |d 1970-  |e VerfasserIn  |0 (DE-588)120850052  |0 (DE-627)705037576  |0 (DE-576)180187163  |4 aut 
700 1 |a Drüschler, Katharina  |e VerfasserIn  |0 (DE-588)1132544726  |0 (DE-627)887869521  |0 (DE-576)488885930  |4 aut 
700 1 |a Wildemann, Brigitte  |e VerfasserIn  |0 (DE-588)110203844  |0 (DE-627)510150004  |0 (DE-576)171831330  |4 aut 
700 1 |a Platten, Michael  |d 1971-  |e VerfasserIn  |0 (DE-588)121627780  |0 (DE-627)081431848  |0 (DE-576)261969811  |4 aut 
700 1 |a Wick, Wolfgang  |d 1970-  |e VerfasserIn  |0 (DE-588)120297736  |0 (DE-627)080586929  |0 (DE-576)186221320  |4 aut 
773 0 8 |i Enthalten in  |t BMJ open  |d London : BMJ Publishing Group, 2011  |g 6(2016,3) Artikel-Nummer e010956, 10 Seiten  |h Online-Ressource  |w (DE-627)654747075  |w (DE-600)2599832-8  |w (DE-576)339269340  |x 2044-6055  |7 nnas  |a Treatment of optic neuritis with erythropoietin (TONE) a randomised, double-blind, placebo-controlled trial : study protocol 
773 1 8 |g volume:6  |g year:2016  |g number:3  |a Treatment of optic neuritis with erythropoietin (TONE) a randomised, double-blind, placebo-controlled trial : study protocol 
856 4 0 |u https://doi.org/10.1136/bmjopen-2015-010956  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://bmjopen.bmj.com/content/6/3/e010956  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20200508 
993 |a Article 
994 |a 2016 
998 |g 120297736  |a Wick, Wolfgang  |m 120297736:Wick, Wolfgang  |d 910000  |d 911100  |e 910000PW120297736  |e 911100PW120297736  |k 0/910000/  |k 1/910000/911100/  |p 30 
998 |g 121627780  |a Platten, Michael  |m 121627780:Platten, Michael  |d 910000  |d 911100  |e 910000PP121627780  |e 911100PP121627780  |k 0/910000/  |k 1/910000/911100/  |p 29 
998 |g 110203844  |a Wildemann, Brigitte  |m 110203844:Wildemann, Brigitte  |d 910000  |d 911100  |e 910000PW110203844  |e 911100PW110203844  |k 0/910000/  |k 1/910000/911100/  |p 28 
998 |g 1132544726  |a Drüschler, Katharina  |m 1132544726:Drüschler, Katharina  |d 910000  |d 911100  |e 910000PD1132544726  |e 911100PD1132544726  |k 0/910000/  |k 1/910000/911100/  |p 5 
998 |g 120850052  |a Beisse, Flemming  |m 120850052:Beisse, Flemming  |d 910000  |d 910900  |e 910000PB120850052  |e 910900PB120850052  |k 0/910000/  |k 1/910000/910900/  |p 3 
998 |g 120119846  |a Diem, Ricarda  |m 120119846:Diem, Ricarda  |d 910000  |d 911100  |e 910000PD120119846  |e 911100PD120119846  |k 0/910000/  |k 1/910000/911100/  |p 1  |x j 
999 |a KXP-PPN1697732232  |e 366283006X 
BIB |a Y 
SER |a journal 
JSO |a {"note":["Gesehen am 08.05.2020"],"id":{"eki":["1697732232"],"doi":["10.1136/bmjopen-2015-010956"]},"title":[{"subtitle":"a randomised, double-blind, placebo-controlled trial : study protocol","title_sort":"Treatment of optic neuritis with erythropoietin (TONE)","title":"Treatment of optic neuritis with erythropoietin (TONE)"}],"recId":"1697732232","language":["eng"],"origin":[{"dateIssuedKey":"2016","dateIssuedDisp":"1 March 2016"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"relHost":[{"pubHistory":["2011 -"],"recId":"654747075","physDesc":[{"extent":"Online-Ressource"}],"part":{"year":"2016","issue":"3","volume":"6","text":"6(2016,3) Artikel-Nummer e010956, 10 Seiten"},"origin":[{"publisher":"BMJ Publishing Group","dateIssuedKey":"2011","publisherPlace":"London","dateIssuedDisp":"2011-"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"language":["eng"],"title":[{"title":"BMJ open","title_sort":"BMJ open"}],"id":{"zdb":["2599832-8"],"eki":["654747075"],"issn":["2044-6055"]},"disp":"Treatment of optic neuritis with erythropoietin (TONE) a randomised, double-blind, placebo-controlled trial : study protocolBMJ open","note":["Gesehen am 02.10.20"]}],"name":{"displayForm":["Ricarda Diem, Fanni Molnar, Flemming Beisse, Nikolai Gross, Katharina Drüschler, Sven P. Heinrich, Lutz Joachimsen, Sebastian Rauer, Amelie Pielen, Kurt-Wolfram Sühs, Ralf Andreas Linker, Cord Huchzermeyer, Philipp Albrecht, Andrea Hassenstein, Orhan Aktas, Tanja Guthoff, Felix Tonagel, Christoph Kernstock, Kathrin Hartmann, Tania Kümpfel, Katharina Hein, Christian van Oterendorp, Birgit Grotejohann, Gabriele Ihorst, Julia Maurer, Matthias Müller, Martin Volkmann, Brigitte Wildemann, Michael Platten, Wolfgang Wick, Christoph Heesen, Ulrich Schiefer, Sebastian Wolf, Wolf A. Lagrèze"]},"person":[{"roleDisplay":"VerfasserIn","family":"Diem","given":"Ricarda","role":"aut","display":"Diem, Ricarda"},{"role":"aut","display":"Beisse, Flemming","given":"Flemming","roleDisplay":"VerfasserIn","family":"Beisse"},{"display":"Drüschler, Katharina","role":"aut","given":"Katharina","family":"Drüschler","roleDisplay":"VerfasserIn"},{"family":"Wildemann","roleDisplay":"VerfasserIn","role":"aut","display":"Wildemann, Brigitte","given":"Brigitte"},{"family":"Platten","roleDisplay":"VerfasserIn","given":"Michael","role":"aut","display":"Platten, Michael"},{"roleDisplay":"VerfasserIn","family":"Wick","role":"aut","display":"Wick, Wolfgang","given":"Wolfgang"}]} 
SRT |a DIEMRICARDTREATMENTO1201